|
시장보고서
상품코드
1973602
임상 유전체 시장 규모, 점유율 및 성장 분석 : 검사 유형별, 방법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Clinical Genomic Market Size, Share, and Growth Analysis, By Test Type (Diagnostic Testing, Genetic Testing), By Method (Molecular Tests, Chromosomal Tests), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 임상 유전체 시장 규모는 2024년에 24억 달러로 평가되었고, 2025년 27억 3,000만 달러에서 2033년까지 75억 6,000만 달러로 성장할 전망입니다. 또한, 예측 기간(2026-2033년) CAGR은 13.6%를 나타낼 것으로 예측됩니다.
세계 임상 유전체 시장은 시퀀싱 비용의 하락과 임상적 유용성 향상으로 인해 괄목할만한 성장을 거듭하고 있습니다. 바이오인포매틱스의 발전은 매우 중요하며, 강력한 해석 과정을 통해 생유전체 데이터를 임상적으로 유용한 지식으로 전환하고 있습니다. 고급 알고리즘과 클라우드 플랫폼의 통합은 실용적인 보고서 제공을 촉진하고, 임상의의 신뢰도를 높이며, 지불자의 상환 모델을 지원합니다. 또한, AI는 돌연변이 검출의 자동화와 해석의 표준화를 통해 진단 정확도를 향상시키는 데 중요한 역할을 하고 있습니다. 여기에는 종양학, 희귀질환, 산전검사의 분석 최적화가 포함됩니다. AI 기반 플랫폼과 의료 시스템과의 연계는 검사실 워크플로우의 효율성을 높이고, 유전체 검사의 임상 도입을 확대하며, 궁극적으로 보다 개인화된 의료 및 표적 치료 옵션을 확대할 수 있을 것으로 기대됩니다.
세계 임상 유전체 시장 성장 촉진요인
세계 임상 유전체 시장의 주요 시장 성장 촉진요인 중 하나는 유전성 질환 및 유전성 질환의 유병률 증가이며, 이는 의료 서비스 제공업체들이 유전체 검사 및 개인 맞춤형 의료 접근법을 채택하도록 유도하고 있습니다. 유전체 염기서열 분석 기술의 발전과 다양한 질병의 유전적 기반에 대한 이해가 깊어짐에 따라 조기 진단과 개인 맞춤형 치료 계획의 실현을 촉진하고 있습니다. 또한, 연구개발에 대한 투자 증가와 헬스케어 분야의 유전체학 진흥을 지원하는 정부 정책은 임상 유전체 솔루션의 도입을 더욱 촉진하여 환자 치료 결과 향상과 시장 전체 성장에 기여하고 있습니다.
세계 임상 유전체 시장 성장 억제요인
세계 임상 유전체 시장의 주요 시장 성장 억제요인 중 하나는 유전체 데이터를 둘러싼 윤리적, 법적, 규제적 문제입니다. 환자의 프라이버시, 데이터 보안, 유전정보의 악용 가능성에 대한 우려가 커지면서 유전체 검사 및 연구 도입에 걸림돌이 될 수 있습니다. 또한, 복잡한 규제 프레임워크와 지역 간 불일치한 가이드라인은 유전체 솔루션을 개발 및 도입하고자 하는 기업에게 장벽이 될 수 있습니다. 이러한 요인들은 의료 제공업체와 환자들 사이에서 주저하게 만들고, 결국 임상 유전체이 일상적인 의료 관행에 통합되는 속도를 늦추고 시장의 성장 잠재력을 제한할 수 있습니다.
세계 임상 유전체 시장 동향
세계 임상 유전체 시장에서는 유전체 검사 기술의 신뢰성과 해석 가능성 향상을 배경으로 임상 워크플로우로의 통합이 두드러진 추세로 진행되고 있습니다. 헬스케어 시스템에서는 검사자, 임상의사, 정보과학 전문가 간의 협력을 통해 유전체 데이터를 진단과 치료에 원활하게 통합하는 데 초점을 맞추었습니다. 이러한 협력을 통해 표준화된 보고서 형식과 의사결정 지원 도구의 개발이 진행되어 임상의의 신뢰 구축과 워크플로우의 혼란을 줄이는데 기여하고 있습니다. 또한, 종합적인 교육, 변경 관리 전략, 상호 운용 가능한 IT 솔루션에 대한 집중적인 노력은 지속 가능한 도입을 촉진하고, 전문 기관을 넘어 유전체학의 임상 적용 범위를 확장하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 임상 유전체 시장 규모 : 검사 유형별&CAGR(2026-2033)
세계의 임상 유전체 시장 규모 : 방법별&CAGR(2026-2033)
세계의 임상 유전체 시장 규모 : 최종사용자별&CAGR(2026-2033)
세계의 임상 유전체 시장 규모&CAGR(2026-2033)
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.04.01Global Clinical Genomic Market size was valued at USD 2.4 Billion in 2024 and is poised to grow from USD 2.73 Billion in 2025 to USD 7.56 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).
The global clinical genomics market is experiencing significant growth driven by the convergence of decreasing sequencing costs and increased clinical utility. Advancements in bioinformatics have been crucial, transforming raw genomic data into clinically useful insights through robust interpretation processes. The integration of advanced algorithms and cloud platforms facilitates the delivery of actionable reports, enhancing clinician trust and supporting payer reimbursement models. Furthermore, AI plays a pivotal role by automating variant detection and harmonizing interpretations, thus improving diagnostic accuracy. This includes optimizing analyses in oncology, rare diseases, and prenatal testing. The collaborations between AI-driven platforms and health systems are poised to enhance laboratory workflow efficiency and broaden the clinical adoption of genomic testing, ultimately leading to more personalized medicine and targeted therapeutic options.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Genomic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Clinical Genomic Market Segments Analysis
Global clinical genomic market is segmented by test type, method, end user and region. Based on test type, the market is segmented into Diagnostic Testing, Genetic Testing, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing and Other Tests. Based on method, the market is segmented into Molecular Tests, Chromosomal Tests and Biochemical Tests. Based on end user, the market is segmented into Hospitals & Clinics, Government Laboratories & Research Centers, Academics and Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Clinical Genomic Market
One of the key market drivers for the global clinical genomics market is the increasing prevalence of genetic disorders and inherited diseases, which is motivating healthcare providers to adopt genomic testing and personalized medicine approaches. Advances in genomic sequencing technologies, coupled with a growing understanding of the genetic underpinnings of various conditions, are facilitating early diagnosis and tailored treatment plans. Additionally, rising investments in research and development, along with supportive government policies promoting genomics in healthcare, are further driving the adoption of clinical genomic solutions, thereby enhancing patient outcomes and contributing to the overall growth of the market.
Restraints in the Global Clinical Genomic Market
One significant market restraint for the global clinical genomic market is the challenge posed by ethical, legal, and regulatory issues surrounding genomic data. The increasing concerns about patient privacy, data security, and potential misuse of genetic information can hinder the adoption of genomic testing and research. Additionally, complex regulatory frameworks and inconsistent guidelines across different regions may create barriers for companies looking to develop and implement genomic solutions. These factors can lead to hesitation among healthcare providers and patients, ultimately slowing down the integration of clinical genomics into routine medical practice and limiting market growth potential.
Market Trends of the Global Clinical Genomic Market
The Global Clinical Genomic market is witnessing a significant trend towards the integration of genomic assays into clinical workflows, driven by enhanced reliability and interpretability of these technologies. Healthcare systems are focusing on the seamless incorporation of genomic data into diagnostic and therapeutic practices, facilitated by collaborative efforts among laboratorians, clinicians, and informatics professionals. This collaboration is leading to the development of standardized report formats and decision support tools, which help build clinician trust and reduce workflow disruptions. Additionally, the emphasis on comprehensive training, change management strategies, and interoperable IT solutions is promoting sustainable implementation, thus broadening the clinical applicability of genomics beyond specialized facilities.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Clinical Genomic Market Size by Test Type & CAGR (2026-2033)
- Market Overview
- Diagnostic Testing
- Genetic Testing
- Newborn Screening
- Preimplantation Testing
- Prenatal Testing
- Carrier Testing
- Other Tests
Global Clinical Genomic Market Size by Method & CAGR (2026-2033)
- Market Overview
- Molecular Tests
- Chromosomal Tests
- Biochemical Tests
Global Clinical Genomic Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals & Clinics
- Government Laboratories & Research Centers
- Academics and Research Institutes
- Other End Users
Global Clinical Genomic Market Size & CAGR (2026-2033)
- North America (Test Type, Method, End User)
- US
- Canada
- Europe (Test Type, Method, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Test Type, Method, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Test Type, Method, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Test Type, Method, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BGI Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomatix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 23andMe
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novogene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Caris Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Invitae
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ArcherDX
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zymeworks
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Freenome
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GRAIL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sophia Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
